IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) is fully enrolled, with topline data expected in the second half of calendar year 2026; all other clinical development timelines remain on track (The Manila Times) - May 20, 2026 - "In calendar year 2027, topline data are expected across potentially registrational trials of IMVT-1402 in GD and MG."
Enrollment closed • P2 data • Cutaneous Lupus Erythematosus • Grave's Disease • Sjogren's Syndrome
|